Perspectives for treating Alzheimer’s disease
a review on promising pharmacological substances
Keywords:
Alzheimer disease, Molecular mechanisms of pharmacological action, Drug therapy, Amyloid beta-peptides, TauopathiesAbstract
CONTEXT AND OBJECTIVE: Dementia is a syndrome characterized by functional and cognitive decline. Alzheimer’s disease (AD) is one of the most common causes of dementia and has high prevalence among the elderly. It is known that there is no drug capable of interfering with the course of the disease. Research on treatments for AD has been marked by the appearance of new drugs and their abandonment. This study aimed to describe drugs that have been studied with regard to treating AD and which are capable of influencing the course of the disease. DESIGN AND SETTING: Narrative review on original articles published worldwide. METHODS: A systematized search was conducted in the PubMed/MEDLINE, Cochrane Library/Cochrane and SciELO/Bireme databases. The descriptors “Molecular Mechanisms of Pharmacological Action” and “Drug Therapy” were each combined with the descriptor “Alzheimer disease”. All of these can be found in MeSH and DeCS. These descriptors were used alone or in combination, and a filter specifying publication between January 2009 and October 2015 in English, Spanish or Portuguese was set. RESULTS: 6,888 articles were found, of which 37 were included in this review; 70.3% of the articles selected were of good quality with low or unclear risk of bias. 86 drugs were considered promising for AD treatment and these were classified into 20 pharmacological categories. CONCLUSION: There are no drugs capable of influencing the course of AD such that treatments are safe and effective. However, immunomodulators stood out as promising, given their effectiveness and quality in the articles analyzed.
Downloads
References
Chaves MLF, Godinho CC, Porto CS, et al. Doença de Alzheimer: avaliação cognitiva, comportamental e funcional. Dement Neuropsychol. 2011;5(supl 1):21-33.
World Health Organization. Neurological disorders: public health challenges. Switzerland: World Health Organization Library Cataloguing-in-Publication Data; 2006. Available from: http://www.who.int/mental_health/neurology/neurological_disorders_report_web.pdf. Accessed in 2016 (Jan 8).
American Psychiatric Association. Delirium, dementia, and amnestic and other cognitive disorders. In: American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. American Psychiatric Association; 1994. p. 123-64. Available from: https://justines2010blog.files.wordpress.com/2011/03/dsm-iv.pdf. Accessed in 2016 (Jan 8).
Larson EB, Kukull WA, Katzman RL. Cognitive impairment: dementia and Alzheimer’s disease. Annu Rev Public Health. 1992;13:431-49.
van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry. 2005;76 Suppl 5:v2-7.
Desai AK, Grossberg GT. Diagnosis and treatment of Alzheimer’s disease. Neurology. 2005;64(12 Suppl 3):S34-9.
Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med. 2004;140(7):501-9.
Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-81.
Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer’s disease. Lancet. 1997;349(9064):1546-9.
Slattum PW, Peron EP, Hill AM. Alzheimer’s disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach. 7th ed. United States: McGraw-Hill; 2008. p. 1051-68.
Lacor PN, Buniel MC, Chang L, et al. Synaptic targeting by Alzheimer’s- related amyloid beta oligomers. J Neurosci. 2004;24(45):10191-200.
Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330(6012):1774.
Inestrosa NC, Alvarez A, Pérez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron. 1996;16(4):881-91.
Dekosky ST, Lopez OL. Alzheimer’s disease. In: Growdon JH, Rossor MN. The Dementias 2. China: Butterworth Heinemann; 2007. p. 33-58.
Tanović A, Alfaro V. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer’s disease and vascular dementia]. Rev Neurol. 2006;42(10):607-16.
Cavalcanti JLS, Engelhardt E. Aspectos da fisiopatologia da doença de Alzheimer esporádica [Pathophysiological features of sporadic Alzheimer’s disease]. Rev Bras Neurol. 2012;48(4):21-9.
Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of
care for patients with dementia resulting from Alzheimer’s disease. Am J Geriatr Psychiatry. 2006;14(7):561-72.
León R, Garcia AG, Marco-Contelles J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med Res Rev. 2013;33(1):139-89.
Konrath EL, Passos Cdos S, Klein LC Jr, Henriques AT. Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer’s disease. J Pharm Pharmacol. 2013;65(12):1701-25.
McGuinness B, O’Hare J, Craig D, et al. Cochrane review on ‘Statins for the treatment of dementia’. Int J Geriatr Psychiatry. 2013;28(2):119-26.
Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer’s disease, role of cytokines. ScientificWorldJournal. 2012;2012:756357.
Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer’s disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013;35(1-2):1-22.
Vale FAC, Corrêa Neto Y, Bertolucci PHF, et al. Tratamento da doença de Alzheimer. Dement Neuropsychol. 2011;5(supl 1):34-48.
Higgins JP, Deeks JJ, Altman DG. Special topics in statistics. In: Higgins JP, Green S, eds. Cochrane handbook for systematic reviews of interventions: Cochrane book series. Chichester: John Wiley & Sons; 2008. p. 481-529.
Pettenati C, Annicchiarico R, Caltagirone C. Clinical pharmacology of anti-Alzheimer drugs. Fundam Clin Pharmacol. 2003;17(6):659-72.
Sun X, Jin L, Ling P. Review of drugs for Alzheimer’s disease. Drug Discov Ther. 2012;6(6):285-90.
Yoo KY, Park SY. Terpenoids as potential anti-Alzheimer’s disease therapeutics. Molecules. 2012;17(3):3524-38.
Dodel R. [Towards a vaccine against Alzheimer’s?]. Drug Res (Stuttg). 2013;63 Suppl 1:S18-20.
Mikulca JA, Nguyen V, Gajdosik DA, et al. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. J Clin Pharm Ther. 2014;39(1):25-37.
Shukla V, Skuntz S, Pant HC. Deregulated Cdk5 activity is involved in inducing Alzheimer’s disease. Arch Med Res. 2012;43(8):655-62.
Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311-21.
Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322-33.
Enciu AM, Popescu BO. Is there a causal link between inflammation and dementia? Biomed Res Int. 2013;2013:316495.
Feng Y, Wang X. Antioxidant therapies for Alzheimer’s disease. Oxid Med Cell Longev. 2012;2012:472932.
Wolfe MS. γ-Secretase inhibitors and modulators for Alzheimer’s disease. J Neurochem. 2012;120 Suppl 1:89-98.
Ghosh AK, Brindisi M, Tang J. Developing β-secretase inhibitors for treatment of Alzheimer’s disease. J Neurochem. 2012;120 Suppl 1:71-83.
Hopkins CR. ACS chemical neuroscience molecule spotlight on ELND006: another γ-secretase inhibitor fails in the clinic. ACS Chem Neurosci. 2011;2(6):279-80.
Piccinni A, Origlia N, Veltri A, et al. Neurodegeneration, β-amyloid and mood disorders: state of the art and future perspectives. Int J Geriatr Psychiatry. 2013;28(7):661-71.
Echeverria V, Zeitlin R. Cotinine: a potential new therapeutic agent against Alzheimer’s disease. CNS Neurosci Ther. 2012;18(7):517-23.
Freiherr J, Hallschmid M, Frey WH 2nd, et al. Intranasal insulin as a treatment for Alzheimer’s disease: a review of basic research and clinical evidence. CNS Drugs. 2013;27(7):505-14.
Morris JK, Burns JM. Insulin: an emerging treatment for Alzheimer’s disease dementia? Curr Neurol Neurosci Rep. 2012;12(5):520-7.
Xu S, Liu G, Bao X, et al. Rosiglitazone prevents amyloid-β oligomer- induced impairment of synapse formation and plasticity via increasing dendrite and spine mitochondrial number. J Alzheimers Dis. 2014;39(2):239-51.
Papadopoulos P, Rosa-Neto P, Rochford J, Hamel E. Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer’s disease with combined amyloid-β and cerebrovascular pathology. PloS One. 2013;8(7):e68612.
Fukasawa H, Nakagomi M, Yamagata N, et al. Tamibarotene: a candidate retinoid drug for Alzheimer’s disease. Biol Pharm Bull. 2012;35(8):1206-12.
Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer’s disease: a meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf. 2013;22(4):345-58.
Calcul L, Zhang B, Jinwal UK, Dickey CA, Baker BJ. Natural products as a rich source of tau-targeting drugs for Alzheimer’s disease. Future Med Chem. 2012;4(13):1751-61.
García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R. Phosphodiesterases as therapeutic targets for Alzheimer’s disease. ACS Chem Neurosci. 2012;3(11):832-44.
Evans DA, Morris MC, Rajan KB. Vitamin E, memantine, and Alzheimer disease. JAMA. 2014;311(1):29-30.
Revett TJ, Baker GB, Jhamandas J, Kar S. Glutamate system, amyloid β peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci. 2013;38(1):6-23.
Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy. 2011;31(5):490-502.
Freund Levi Y, Vedin I, Cederholm T, et al. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer’s disease: the OmegAD study. J Intern Med. 2014;275(4):428-36.
Sun GY, He Y, Chuang DY, et al. Integrating cytosolic phospholipase A2 with oxidative/nitrosative signaling pathways in neurons: a novel therapeutic strategy for AD. Mol Neurobiol. 2012;46(1):85-95.
Koliaki CC, Messini C, Tsolaki M. Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study. CNS Neurosci Ther. 2012;18(4):302-12.
Maki PM, Henderson VW. Hormone therapy, dementia, and cognition: the Women’s Health Initiative 10 years on. Climacteric. 2012;15(3):256-62.
Anekonda TS, Quinn JF. Calcium channel blocking as a therapeutic strategy for Alzheimer’s disease: the case for isradipine. Biochim Biophys Acta. 2011;1812(12):1584-90.
Valenzuela M, Esler M, Ritchie K, Brodaty H. Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention. Transl Psychiatry. 2012;2:e107.
